Salt Lake City, UT, June 9, 2026. NanoKar Therapeutics, Inc. (“NanoKar”), a biotechnology company developing next-generation CAR-T cell therapies, announced today that it has been accepted into the Innosphere Ventures accelerator program, a leading science and technology incubator based in Fort Collins, Colorado. Innosphere is recognized as one of the top university-affiliated business incubators in the world and provides critical resources including mentorship, business development support, and access to capital for high-growth startups in the life science and technology sectors.
Acceptance into the Innosphere Ventures accelerator program represents a significant milestone for NanoKar. Through the program, NanoKar will gain access to a curated network of experienced mentors, seasoned investors, and business advisory services tailored to the unique challenges of early-stage biotechnology companies. Innosphere’s collaborative environment is specifically designed to accelerate the commercialization of innovative technologies, and its deep expertise in supporting life science and biotechnology companies makes it an ideal partner for NanoKar as the company advances its proprietary CAR-T cell therapy platform toward clinical development and strategic partnerships.
“We are thrilled to join the Innosphere Ventures accelerator program at such a pivotal time for NanoKar. Innosphere’s proven track record of helping science-based companies scale and succeed aligns perfectly with our mission. The mentorship, investor access, and business development resources available through the program will be instrumental in accelerating our path to strategic partnerships and advancing our CAR-T platform toward key clinical development milestones. We look forward to working alongside the Innosphere team and the broader innovation community in Colorado.”
Craig Mosman, J.D. · Chief Executive Officer
Innosphere Ventures has established itself as a premier incubator and accelerator in the Mountain West region, with a strong legacy of supporting high-impact startups from concept through commercialization. The program has helped hundreds of companies raise capital, secure partnerships, and bring transformative technologies to market across the life sciences, medical devices, clean energy, and advanced technology sectors. Innosphere’s connection to Colorado’s robust research universities and innovation ecosystem provides portfolio companies with unparalleled access to talent, facilities, and collaborative opportunities.
NanoKar plans to leverage the Innosphere program to refine its go-to-market strategy, strengthen its business development capabilities, and engage with potential partners and investors who share the company’s vision for the future of cell therapy. NanoKar’s proprietary platform technology is designed to address the critical limitations of current CAR-T therapies, including T-cell exhaustion and limited efficacy against solid tumors. As the company advances this platform, the resources and strategic support provided by Innosphere will play a key role in positioning the company for its next phase of growth and clinical advancement.
About NanoKar Therapeutics
NanoKar Therapeutics, Inc. is a biotechnology company focused on developing next-generation CAR-T cell therapies. Founded on breakthrough research from the University of Utah, NanoKar’s proprietary platform technology is designed to overcome the key limitations of current CAR-T therapies, including T-cell exhaustion and limited efficacy against solid tumors. The company is committed to advancing its platform through strategic partnerships and clinical development to bring transformative cell therapies to patients in need.
For more information, visit www.nanokartherapeutics.com.
Media Contact
NanoKar Therapeutics, Inc. craig@nanokartherapeutics.com